1. N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition
- Author
-
Laura Scalvini, Gilberto Spadoni, Alessio Lodola, Giorgio Tarzia, Daniele Piomelli, Marco Mor, and Yannick Fotio
- Subjects
Agonist ,medicine.drug_class ,Anti-Inflammatory Agents ,Inflammation ,Palmitic Acids ,01 natural sciences ,Amidohydrolases ,Amidase ,03 medical and health sciences ,chemistry.chemical_compound ,Drug Discovery ,Hydrolase ,medicine ,Animals ,Humans ,Amino Acid Sequence ,Cysteine ,Enzyme Inhibitors ,Receptor ,030304 developmental biology ,0303 health sciences ,Palmitoylethanolamide ,Peroxisome ,Amides ,0104 chemical sciences ,Ethanolamines ,Sequence Alignment ,Signal Transduction ,010404 medicinal & biomolecular chemistry ,chemistry ,Biochemistry ,Molecular Medicine ,medicine.symptom - Abstract
N-Acylethanolamine acid amidase (NAAA) is an N-terminal cysteine hydrolase primarily found in the endosomal-lysosomal compartment of innate and adaptive immune cells. NAAA catalyzes the hydrolytic deactivation of palmitoylethanolamide (PEA), a lipid-derived peroxisome proliferator-activated receptor-α (PPAR-α) agonist that exerts profound anti-inflammatory effects in animal models. Emerging evidence points to NAAA-regulated PEA signaling at PPAR-α as a critical control point for the induction and the resolution of inflammation and to NAAA itself as a target for anti-inflammatory medicines. The present Perspective discusses three key aspects of this hypothesis: the role of NAAA in controlling the signaling activity of PEA; the structural bases for NAAA function and inhibition by covalent and noncovalent agents; and finally, the potential value of NAAA-targeting drugs in the treatment of human inflammatory disorders.
- Published
- 2020